April 19th, 2022 (Earnings Report)Dear Reader,We just identified several healthtech stocks that are expected to release earnings this week.If you are interested in any of these companies, we encourage you to do your own research and due diligence before pursuing any investments.Keep in mind, the actual earnings date and time may change, so if you’re interested in any of these companies you will need to pay close attention to their announcements.
Johnson & Johnson
Symbol: JNJ
Recent Price: $177.66
Average Analyst Price Target: $188.73 (6.23%)
Market Cap: $467.18B
Last Year's EPS: $2.59
Consensus EPS Forecast: $2.58
Expected Earnings Date: Apr 18 2022
Recent Analyst Action: Jayson Bedford, analyst at Raymond James, reiterates coverage on Johnson & Johnson (JNJ) in the Healthcare sector with a Buy rating and a price target of $ 195 (5 days ago).
TipRanks.com also reports that Johnson & Johnson currently has 11 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $188.73 . The target pricing ranges from a high forecast of $215.00 down to a low forecast of $173.00. Johnson & Johnson (JNJ)’s last closing price was $177.66 which would put the average price target at 6.23% upside.Here are 3rd party ratings for JNJ:
- TipRanks.com: Moderate Buy
- TradingView.com: Neutral
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 36% (92 out of 253)
--------------------------------------------------------------------------
Rubicon Organics
Symbol: ROMJF
Recent Price: $0.98
Average Analyst Price Target: $2.77 (182.65%)
Market Cap: $54.86M
Last Year's EPS: -$0.06
Consensus EPS Forecast: ―
Expected Earnings Date: Apr 17 2022
Recent Analyst Action: Rahul Sarugaser, analyst at Raymond James, reiterates coverage on Rubicon Organics (ROMJF) in the Healthcare sector with a Buy rating and a price target of $ 2.77 (1 day ago).
TipRanks.com also reports that Rubicon Organics currently has 1 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $2.77 . The target pricing ranges from a high forecast of $2.77 down to a low forecast of $2.77. Rubicon Organics (ROMJF)’s last closing price was $0.98 which would put the average price target at 182.65% upside.Here are 3rd party ratings for ROMJF:
- TipRanks.com: Moderate Buy
- TradingView.com: n/a
- Yahoo! Finance: Neutral Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: n/a, n/a
--------------------------------------------------------------------------
Abbott Labs
Symbol: ABT
Recent Price: $116.29
Average Analyst Price Target: $143.22 (23.16%)
Market Cap: $205.08B
Last Year's EPS: $1.32
Consensus EPS Forecast: $1.47
Expected Earnings Date: Apr 19 2022
Recent Analyst Action: Larry Biegelsen, analyst at Wells Fargo, reiterates coverage on Abbott Labs (ABT) in the Healthcare sector with a Buy rating and a price target of $ 150 (1 week ago).
TipRanks.com also reports that Abbott Labs currently has 9 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $143.22 . The target pricing ranges from a high forecast of $151.00 down to a low forecast of $138.00. Abbott Labs (ABT)’s last closing price was $116.29 which would put the average price target at 23.16% upside.Here are 3rd party ratings for ABT:
- TipRanks.com: Strong Buy
- TradingView.com: Strong Sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Bottom 39% (154 out of 253)
--------------------------------------------------------------------------
Anthem
Symbol: ANTM
Recent Price: $512.95
Average Analyst Price Target: $495.00 (-3.50%)
Market Cap: $123.74B
Last Year's EPS: $7.01
Consensus EPS Forecast: $7.85
Expected Earnings Date: Apr 19 2022
Recent Analyst Action: Ann Hynes, analyst at Mizuho Securities, reiterates coverage on Anthem (ANTM) in the Healthcare sector with a Buy rating and a price target of $ 510 (1 week ago).
TipRanks.com also reports that Anthem currently has 16 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $495.00 . The target pricing ranges from a high forecast of $590.00 down to a low forecast of $335.00. Anthem (ANTM)’s last closing price was $512.95 which would put the average price target at -3.50% upside.Here are 3rd party ratings for ANTM:
- TipRanks.com: Strong Buy
- TradingView.com: Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 33% (83 out of 253)
--------------------------------------------------------------------------
Imac Holdings
Symbol: IMAC
Recent Price: $0.8301
Average Analyst Price Target: n/a ()
Market Cap: $21.99M
Last Year's EPS: -$0.15
Consensus EPS Forecast: ―
Expected Earnings Date: Apr 19 2022
Recent Analyst Action: Jason Kolbert, analyst at Dawson James, reiterates coverage on Imac Holdings (IMAC) in the Healthcare sector with a Hold rating and a price target of n/a (3 weeks ago).
TipRanks.com also reports that Imac Holdings currently has n/a analysts offering 12-month price targets and the consensus is a Hold rating with an average price target is n/a . The target pricing ranges from a high forecast of n/a down to a low forecast of n/a. Imac Holdings (IMAC)’s last closing price was $0.8301 which would put the average price target at upside.Here are 3rd party ratings for IMAC:
- TipRanks.com: Hold
- TradingView.com: Sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Bottom 31% (174 out of 253)
--------------------------------------------------------------------------
Oxford BioMedica
Symbol: OXBDF
Recent Price: $8.35
Average Analyst Price Target: $24.74 (196.29%)
Market Cap: $802.14M
Last Year's EPS: <$0.01
Consensus EPS Forecast: $0.11
Expected Earnings Date: Apr 19 2022
Recent Analyst Action: Charles Weston, analyst at RBC Capital, reiterates coverage on Oxford BioMedica (OXBDF) in the Healthcare sector with a Buy rating and a price target of $ 18.17 (3 weeks ago).
TipRanks.com also reports that Oxford BioMedica currently has 2 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $24.74 . The target pricing ranges from a high forecast of $31.31 down to a low forecast of $18.17. Oxford BioMedica (OXBDF)’s last closing price was $8.35 which would put the average price target at 196.29% upside.Here are 3rd party ratings for OXBDF:
- TipRanks.com: Moderate Buy
- TradingView.com: n/a
- Yahoo! Finance: Neutral Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Bottom 39% (154 out of 253)
--------------------------------------------------------------------------
Tenet Healthcare
Symbol: THC
Recent Price: $84.15
Average Analyst Price Target: $105.29 (25.12%)
Market Cap: $9.19B
Last Year's EPS: $1.3
Consensus EPS Forecast: $1.01
Expected Earnings Date: Apr 19 2022
Recent Analyst Action: Whit Mayo, analyst at Leerink Partners, reiterates coverage on Tenet Healthcare (THC) in the Healthcare sector with a Buy rating and a price target of $ 100 (5 days ago).
TipRanks.com also reports that Tenet Healthcare currently has 14 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $105.29 . The target pricing ranges from a high forecast of $125.00 down to a low forecast of $89.00. Tenet Healthcare (THC)’s last closing price was $84.15 which would put the average price target at 25.12% upside.Here are 3rd party ratings for THC:
- TipRanks.com: Strong Buy
- TradingView.com: Sell
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: buy
- Zacks.com: Hold, Top 30% (76 out of 253)
--------------------------------------------------------------------------
To Your Financial Future,
The Editor, HealthTechMovers.com
